Compare OGG & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGG | IVA |
|---|---|---|
| Founded | N/A | 2011 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.5M | 895.3M |
| IPO Year | 2008 | 2020 |
| Metric | OGG | IVA |
|---|---|---|
| Price | $2.72 | $3.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $16.20 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | N/A | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $751.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $3.35 |
| 52 Week High | $3.30 | $7.98 |
| Indicator | OGG | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 27.70 |
| Support Level | $2.69 | $3.35 |
| Resistance Level | $2.89 | $4.78 |
| Average True Range (ATR) | 0.12 | 0.27 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 30.39 | 2.78 |
Osisko Gold Group Inc is a continental North American gold development company focused on past producing mining camps with district-scale potential. The company's objective is to become an intermediate gold producer through the development of its flagship, Cariboo Gold Project, located in central British Columbia, Canada. Its project portfolio also includes the Tintic Project in the East Tintic mining district of Utah, United States.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.